Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

142 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 142 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243938
What this trial is testing

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Who this might be right for
Locally Advanced Rectal Cancer (LARC)Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaMetastatic Colorectal Cancer (mCRC)+1 more
Tao Zhang 70
Testing effectiveness (Phase 2)Looking for participantsNCT05671822
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Who this might be right for
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 258
Testing effectiveness (Phase 2)Study completedNCT02689284
What this trial is testing

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerStomach CancerEsophageal Cancer
MacroGenics 95
Early research (Phase 1)Study completedNCT04513223
What this trial is testing

SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Gastric CancerColorectal Cancer
Jiangsu HengRui Medicine Co., Ltd. 101
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Large-scale testing (Phase 3)Looking for participantsNCT07315750
What this trial is testing

Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 555
Not applicableLooking for participantsNCT06158919
What this trial is testing

PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Who this might be right for
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University 58
Early research (Phase 1)Looking for participantsNCT04389632
What this trial is testing

Sigvotatug Vedotin in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer 1,006
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Testing effectiveness (Phase 2)Study completedNCT03929666
What this trial is testing

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Who this might be right for
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals 74
Large-scale testing (Phase 3)Study completedNCT00680901
What this trial is testing

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Who this might be right for
Neoplasms, Gastrointestinal Tract
Novartis Pharmaceuticals 545
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Testing effectiveness (Phase 2)Ended earlyNCT01774851
What this trial is testing

MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Who this might be right for
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more
Merrimack Pharmaceuticals 84
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Testing effectiveness (Phase 2)UnknownNCT05188209
What this trial is testing

Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Who this might be right for
Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Carcinoma
Shanghai Miracogen Inc. 60
Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)UnknownNCT05113459
What this trial is testing

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Who this might be right for
Gastric Cancer
Guoxin Li 40
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Load More Results
377